EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Ocular Toxoplasmosis: Bridging Clinical Diagnosis and Evidence-Based Management

Katarzyna Gunia, Gabriela Grylowska, Anna Paluch, Aleksandra Adamczyk, Agata Żak, Andrzej Palak, Marcin Rebizant, Mateusz Banasik, Michał Tryba, Anna Ignatowicz

Quality in Sport · 13.07.2026 · 63 · 73348

DOI: 10.12775/qs.2026.63.73348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Quality in Sport, online erschienen am 13.07.2026. Verfasst von Katarzyna Gunia und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ocular toxoplasmosis is one of the most common infectious causes of posterior uveitis and may lead to recurrent inflammation and visual impairment. It most often presents as necrotizing retinochoroiditis, but the clinical picture depends on lesion location and immune status.

Aim

This review summarizes current evidence on clinical manifestations, diagnosis and treatment of ocular toxoplasmosis. Material and methods: A narrative review of PubMed and Scopus publications from 2002–2025 was performed, focusing on clinical presentation, diagnostic methods and therapeutic management.

Results

Ocular toxoplasmosis usually presents as focal retinochoroiditis with vitritis and, less commonly, anterior uveitis. Immunocompromised patients may develop bilateral, multifocal or extensive lesions. Diagnosis is primarily clinical and may be supported by serology, multimodal imaging, PCR testing and assessment of intraocular antibody production in uncertain cases. Conventional therapy with pyrimethamine, sulfadiazine and corticosteroids remains effective, while trimethoprim-sulfamethoxazole offers comparable efficacy with a more favorable safety profile. Intravitreal clindamycin with dexamethasone may be considered when systemic treatment is contraindicated.

Conclusions

Early diagnosis and individualized treatment are essential to reduce irreversible retinal damage. Current therapies control active inflammation but do not eradicate latent infection or reliably prevent recurrence.

Zitieren

APA

Gunia, K., Grylowska, G., Paluch, A., Adamczyk, A., Żak, A., Palak, A., Rebizant, M., Banasik, M., Tryba, M., & Ignatowicz, A. (2026). Ocular Toxoplasmosis: Bridging Clinical Diagnosis and Evidence-Based Management. Quality in Sport, 63, 73348. https://doi.org/10.12775/qs.2026.63.73348

Vancouver

Gunia K, Grylowska G, Paluch A, Adamczyk A, Żak A, Palak A, et al. Ocular Toxoplasmosis: Bridging Clinical Diagnosis and Evidence-Based Management. Quality in Sport. 2026;63:73348. doi:10.12775/qs.2026.63.73348

BibTeX
@article{Gunia2026,
  author = {Gunia, Katarzyna and Grylowska, Gabriela and Paluch, Anna and Adamczyk, Aleksandra and Żak, Agata and Palak, Andrzej and Rebizant, Marcin and Banasik, Mateusz and Tryba, Michał and Ignatowicz, Anna},
  title = {Ocular Toxoplasmosis: Bridging Clinical Diagnosis and Evidence-Based Management},
  journal = {Quality in Sport},
  year = {2026},
  volume = {63},
  pages = {73348},
  doi = {10.12775/qs.2026.63.73348}
}
Kostenlos starten →